Protective effects of vasoactive intestinal peptide (VIP) in ischemic retinal degeneration

K. Szabadfi, B. Danyadi, P. Kiss, A. Tamas, E. Fabian, R. Gabriel, D. Reglodi

Research output: Contribution to journalArticle

15 Citations (Scopus)


Vasoactive intestinal peptide (VIP) is a pleiotropic neuropeptide, acting as a neuromodulator and neuroprotective peptide in the CNS after injuries. We have previously described that pituitary adenylate cyclaseactivating polypeptide (PACAP), another member of the same peptide family, is retinoprotective in ischemic lesions. The aim of this study was to investigate the protective potential of VIP in bilateral common carotid artery occlusion (BCCAO)-induced ischemic retinal lesion. Two-month-old rats were subjected to BCCAO and treated with intravitreal VIP injection. Their retinas were processed for histology after 2 weeks of survival. We measured the number of the cells/100 μm of the ganglion cell layer and the thickness of each layer such as the outer nuclear, outer plexiform, inner nuclear, and inner plexiform layers as well as that of the whole retina. We found that treatment with 1,000 pmolVIP, but not 100 pmolVIP, had significant protective effects in BCCAO-injured retina, as shown by the morphometric analysis. Comparing the neuroprotective effects of VIP and PACAP in BCCAOoperated retinas, PACAP was more effective, already protective at 100-pmol doses. Similar to other studies, we found that VIP must be given at least in 10 times more concentration than PACAP to achieve a similar degree of neuroprotection in the retina.

Original languageEnglish
Pages (from-to)501-507
Number of pages7
JournalJournal of Molecular Neuroscience
Issue number3
Publication statusPublished - Nov 1 2012



  • Ischemia
  • Protection
  • Retina
  • VIP

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this